# Safety and Tolerability of Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) - a Pilot Study

> **NCT07660107** · NA · COMPLETED · sponsor: **Kioga Inc.** · enrollment: 8 (actual)

## Conditions studied

- Safety
- Tolerability

## Interventions

- **DIETARY_SUPPLEMENT:** Heat-killed Mycolicibacterium petrae KGA-10 (NeuroAlly)
- **DIETARY_SUPPLEMENT:** Placebo (microcrystalline cellulose)

## Key facts

- **NCT ID:** NCT07660107
- **Lead sponsor:** Kioga Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-07
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660107, "Safety and Tolerability of Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) - a Pilot Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07660107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*